Carcinomas epiteliales del ovario de alto y bajo grado: Estado de Arte
Epithelial carcinomas of the ovary of high and low grade: State of Art
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Mostrar biografía de los autores
El cáncer epitelial del ovario en Colombia es la segunda causa de morbilidad y mortalidad por tumores ginecológicos después del carcinoma de cuello uterino. Por lo regular se presenta en estados avanzados y la sobrevida es pobre. Recientes estudios de tipo clínicopatológicos y moleculares han develado nuevas teorías sobre la carcinogénesis, proponiendo un modelo dual con tumores tipos I y II. Se busca con este artículo ampliar y actualizar la información sobre estas nuevas teorías y profundizar en el conocimiento histopatológico y molecular. Para la revisión de la literatura se estructuró una estrategia de búsqueda utilizando los términos carcinoma de ovario, tumores tipo I-II, KRAS, BRAF, p-53 (MeSH y no Mesh), los cuales se articularon con operadores booleanos en las siguientes bases de datos: pubmed, ebscohost, embase, filtrando los resultados por artículos de revisión.
Visitas del artículo 687 | Visitas PDF 2194
Descargas
1. Intenational Agency for research On Cancer. Globocan 2012. Estimated incidence, mortality and prevalence worldwide in 2012 [monograph on the Internet]. Lyon, France: Worl Health Organitation; 2012 [cited 2015 Mar 10]. Disponible en: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.
2. Lim D, Oliva E. Precursors and pathogenesis of ovarian carcinoma. Pathology. 2013; 45(3):229-42.
3. Gong TT, Wu QJ, Vogtmann E, Lin B, Wang YL. Age at menarche and risk of ovarian cancer: a meta-analysis of epidemiological studies. Int J Cancer. 2013; 132(12):2894-900.
4. Faber MT, Kjær SK, Dehlendorff C, Chang-Claude J, Andersen KK, Hogdall E, et al. Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case–control studies. Cancer Causes Control. 2013; 24(5):989-1004
5. Blaustein A, Kurman RJ, Elleson LH, Ronnett BM. Patología del tracto genital femenino de Blaustein. 7th ed. Caracas : Amolca; 2014.
6. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15.
7. Novoa-Vargas A. [Natural history of ovary cancer]. Ginecol Obstet Mex. 2014; 82(9):613-22.
8. Farghaly SA. The role of oral contraceptive pills (OCPs) in chemoprevention of epithelial ovarian cancer in women with mutant BRCA1 and BRCA2 Genes. J Cancer Sci Ther. 2013; 5(8): 1000–124.
9. Kohn EC, Hurteau J. Ovarian cancer : making its own rules-again. Cancer. 2013; 119(3):474-6.
10. Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int. 2014;2014:934261.
11. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011; 61(3):183-203.
12. Prat J. New insights into ovarian cancer pathology. Ann Oncol. 2012 Sep;23 Suppl 10:x111-7
13. del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol. 2012; 126(3):481-90.
14. Okamoto A, Glasspool RM, Mabuchi S, Matsumura N, Nomura H, Itamochi H, et al. Gynecologic cancer inter group (GCIG) consensus review for clear cell carcinoma of the ovary. Int J Gynecol Cancer. 2014; 24(9 Suppl 3):S20-5.
15. Dabbs DJ. Diagnostic immunohistochemistry. 4th ed. Philadelphia: Saunders; 2014. 960 p.
16. Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol. 2003; 163(6):2503-12.
17. Okamoto T, Mandai M, Matsumura N, Yamaguchi K, Kondoh H, Amano Y, et al. Hepatocyte nuclear factor-1beta (HNF-1beta) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma. Mol Carcinog. 2015 ;54(1):35-49.
18. Maeda D, Shih Ie M. Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms. Adv Anat Pathol. 2013; 20(1):45-52.
19. Kajihara H, Yamada Y, Shigetomi H, Higashiura Y, Kobayashi H. The dichotomy in the histogenesis of endometriosis-associated ovarian cancer: clear celltype versus endometrioid-type adenocarcinoma. Int J Gynecol Pathol. 2012; 31(4):304-12.
20. Shappell HW, Riopel MA, Smith Sehdev AE, Ronnett BM, Kurman RJ. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol. 2002; 26(12):1529-41.
21. Ledermann JA, Luvero D, Shafer A, O’Connor D, Mangili G, Friedlander M, et al. Gynecologic cancer intergroup (gcig) consensus review for mucinous ovarian carcinoma. Int J Gynecol Cancer. 2014; 24(9 Suppl 3):S14-9.
22. Frumovitz M, Schmeler KM, Malpica A, Sood AK, Gershenson DM. Unmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol. 2010; 117(3):491–6.
23. Rechsteiner M, Zimmermann AK, Wild PJ, Caduff R, von Teichman A, et al. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Exp Mol Pathol. 2013 Oct;95(2):235-41.
24. Gourley C, Farley J, Provencher DM, Pignata S, Mileshkin L, Harter P, et al. Gynecologic cancer intergroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas. Int J Gynecol Cancer. 2014; 24(9 Suppl 3):S9-s13.
25. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011; 43(5):420-32.
26. Boyd J, Luo B, Peri S, Wirchansky B, Hughes L, Forsythe C, et al. Whole exome sequence analysis of serous borderline tumors of the ovary. Gynecol Oncol. 2013; 130(3):560-4.
27. Grisham RN, Iyer G, Garg K, DeLair D, Hyman DM, Zhou Q et al. BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer. 2014; 119(3):548-54.
28. Ingin RJ, Andola SK, Zubair AA. Transitional cell carcinoma of the ovary: case series and review of literature. J Clin Diagn Res. 2014; 8(8):FD07-8.
29. Kurman RJ, Elleson LH, Ronnett BM. Patología del tracto genital femenino de Blaustein. 7a ed. Caracas: Amolca; 2014.
30. Roma AA, Masand RP. Ovarian Brenner tumors and Walthard nests: a histologic and immunohistochemical study. Hum Pathol. 2014; 45(12):2417-22
31. Kommoss F, Kommoss S, Eichhorn J, Schmidt D. [Transitional cell carcinoma of the ovary. Morphological and clinical features]. Pathologe. 2007; 28(3):209-14.
32. Hannibala CG, Vang R, Junge J, Kjaerbye-Thygesen A, Kurman RJ, Kjaer SK. A Binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4,317 women diagnosed in denmark 1978-2006. Gynecol Oncol. 2012;125(3):655-60.
33. Diniz PM, Carvalho JP, Baracat EC, Carvalho FM. Fallopian tube origin of supposed ovarian high-grade serous carcinomas. Clinics (Sao Paulo). 2011; 66(1):73-6.
34. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001; 195(4):451-6.
35. Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol. 2013; 24 Suppl 10:x16-21.
36. Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih Ie M, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol. 2011; 24(9):1248-53.
37. Chene G, Rahimi K, Mes-Masson AM, Provencher D. Surgical implications of the potential new tubal pathway for ovarian carcinogenesis. J Minim Invasive Gynecol. 2013; 20(2):153-9.
38. Chen EY, Mehra K, Mehrad M, Ning G, Miron A, Mutter GL, et al. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol. 2010; 222(1):110-6.
39. Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma - evidence supporting the clonal relationship of the two lesions. J Pathol. 2012; 226(3):421-6.
40. Rabban JT, Krasik E, Chen LM, Powell CB, Crawford B, Zaloudek CJ. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingooophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol. Am J Surg Pathol. 2009; 33(12):1878-85.
41. Reed NS, Pautier P, Avall-Lundqvist E, Choi CH, du Bois A, Friedlander M, et al. Gynecologic cancer intergroup (GCIG) consensus review for ovarian small cell cancers. Int J Gynecol Cancer. 2014; 24(9 Suppl 3):S30-4.
42. Ki EY, Park JS, Lee KH, Bae SN, Hur SY. Large cell neuroendocrine carcinoma of the ovary: a case report and a brief review of the literature. World J Surg Oncol. 2014; 12(1):314.
43. Ramos P, Karnezis AN, Craig DW, Sekulic A, Russell ML, Hendricks WP, et al. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet. 2014; 46(5):427-9.
44. Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, et al. Gynecologic cancer intergroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer. 2014; 24(9 Suppl 3):S55-60.
45. Lamb MR, Gertsen E, Middlemas E. Carcinosarcoma of the ovary: case report and literature review. Tenn Med. 2012; 105(3):41-2.
46. del Carmen MG, Birrer M, Schorge JO. Carcinosarcoma of the ovary: a review of the literature. Gynecol Oncol. 2012; 125(1):271-7.
47. Growdon WB, Roussel BN, Scialabba VL, Foster R, Dias-Santagata D, Iafrate AJ, et al. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin. Gynecol Oncol. 2011; 121(1):212-7.
48. Reade CJ, Finlayson S, McAlpine J, Tone AA, Fung-Kee-Fung M, Ferguson SE. Risk-reducing salpingectomy in Canada: a survey of obstetrician-gynaecologists. J Obstet Gynaecol Can. 2013; 35(7):627-34.
49. Yokoyama Y, Mizunuma H. Recurrent epithelial ovarian cancer and hormone therapy. World J Clin Cases. 2013; 1(6):187-90.
50. Schenberg T, Mitchell G. Prophylactic bilateral salpingectomy as a prevention strategy in women at high-Risk of ovarian cancer: a mini-review. Front Oncol. 2014;4:1-4
51. Kurta ML, Edwards RP, Moysich KB, McDonough K, Bertolet M, Weissfeld JL, et al. Prognosis and conditional disease-free survival among patients with ovarian cancer. J Clin Oncol. 2014; 32(36):4102-12.
Información
Palabras clave
